Kolkata-based healthtech platform iKure has raised an undisclosed amount of funding from Inflection Point Ventures (IPV).
The startup plans to use the funds for business and technology expansion, an official statement said.
iKure was founded in 2010 by Sujay Santra who had previously worked with IBM and Oracle. The company currently operates eight primary healthcare clinics, six mini-clinics and conducts more than five health intervention programmes per week.
iKure is a social health enterprise engaged in delivering primary healthcare, wellness and prevention services to rural, semi-urban and urban population, the statement said.
The company has so far covered 3,000-plus villages across seven states, profiled 58 diseases and trained more than 550 community healthcare workers. iKure claims to have touched eight million people in India, eight countries internationally and aims to serve 25 million underserved people over the next four years.
The company also licences out its proprietary technology platform and undertakes commissioned survey and research projects, the statement added.
“Our journey with IPV has been very enriching. They are one of the most professional groups in India when it comes to raising capital. There is also the added benefit of accessing the IPV network comprising of more than 250 CXOs across various companies,” said Santra in the statement.
“iKure is integrating technology and medical expertise to address the last mile healthcare delivery challenges in rural India. The impact that this can bring is huge, both from a social and economic perspective. iKure has got initial success and has struck the right model,” said Rahul Verma, angel investor, IPV.
Recent deals in the space:
Healthtech startup PlusPin Healthcare raised $700,000 in a seed funding round led by seed-stage investment network Indian Angel Network (IAN).
Health and fitness app Fitso raised $1.5 million in pre-Series A funding round.
Fitness device maker GOQii Technologies raised over $6.3 million from Bennett Coleman and Company (BCCL).